In addition, 20–35% of DLBCL cases show co-expression of MYC and BCL2 by immunohistochemistry in the absence of chromosomal translocations, which represent “double expressor” lymphomas (DEL) also associated with poor clinical outcome, but are mainly of the ABC subtype [22]. The gene discussed is MYC; the disease is lymphoma.